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p-value < 0.001) ConClusions: BMI was negatively associated with HRQoL based 
on the multivariate regression analysis among Korean diabetic patients with HbA1c 
≥ 6.5, after adjusting for confounding factors. This finding alerts diabetic patients to 
the danger of the weight gain as it is related to the lower quality of life.
PDB98
HealtH-RelateD Quality of life in Patients witH tyPe 1 DiaBetes anD 
imPaiReD HyPoglycaemia awaReness: tHe Role of sensoR-augmenteD 
insulin PumP tHeRaPy witH automateD insulin susPension
McBride M.1, Eggleston A.S.2, Jones T.3, Ly T.3
1Medtronic Australasia Ltd., North Ryde, NSW, Australia, 2*Medtronic International Ltd., North 
Ryde, Australia, 3Princess Margaret Hospital for Children, Perth, WA, Australia
introduCtion: Compared with multiple daily injections, insulin pump therapy 
(continuous subcutaneous insulin infusion - CSII) improves glucose control in 
patients with type 1 diabetes mellitus (T1DM). When CSII is combined with continu-
ous glucose monitoring (CGM) with automated low glucose insulin suspension (LGS), 
exposure to hypoglycaemia is significantly reduced. Patients with impaired hypogly-
caemia awareness (IHA) are at increased risk of severe hypoglycaemia, so the ben-
efits of this technology should be evident in patient reported health-related quality 
of life (HRQoL). objeCtives: To compare HRQoL in T1DM patients with IHA treated 
with CSII alone or CSII with CGM + LGS in this 6 month, prospective, single centre 
RCT. Methods: T1DM patients with IHA and CSII experience were randomised to 
either CSII alone (control, n= 49) or CSII with CGM + LGS (treatment, n= 46). Patients 
> 12 years were included in this analysis (n= 64, male 50%, age 23.2 ± 11.9 years, 
diabetes duration 13.8 ± 9.5 years, CSII duration 4.9 ± 3.6 years, Hypoglycaemia 
Awareness score 6.2 ± 1.4). Hypoglycaemia Fear survey (HFS) and HRQoL (EQ5D) 
were analysed using ANCOVA least-squares mean change from baseline to 6 months 
post-randomisation. results: Enrolled patients were not appreciably impaired at 
baseline (EQ5D Utility mean +SD 0.96+0.07), but overall gains in treatment group 
(+0.038) and decrements in control (-0.035) over 6 months produced a significant 
comparative utility gain for the intervention (LS mean difference 0.073, 95% CI: 
0.008-0.139, p= 0.028). Although not statistically significant, supporting trends were 
noted in EQ5D VAS and HFS (Worry subscale). ConClusions: Success of T1DM 
treatment relies upon effective and compliant self-management, so the patient 
perspective is relevant when evaluating treatment options and determining the 
impact on aspects of daily life. This analysis further supports the important role of 
insulin pump therapy plus CGM with automated LGS in the effective management 
of T1DM patients with IHA.
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objeCtives: To analyse the quality of life in insulin-dependent patients and 
resource consumption due to poor metabolic control after the standarization of 
glycated hemoglobin measure with A1CNOW+ and the glycemia measure with 
CONTOUR USB. Methods: An observational, prospective, multicentre study in 
patients with diabetes, insulin-dependent, with poor metabolic control has been 
conducted. Distribution of the ESDQOL questionnaire which contains the domains 
satisfaction, impact, social /vocational, concern regarding diabetes and degree of 
perception of QoL at baseline, at 3 and 6 months. The score of the domains and the 
full questionnaire is measured on a scale 0-100; where lower scores indicate a higher 
QoL. Also, Visual Analogic Scale was used to assess the patient’s own perception 
of their quality of life. The resource consumption is analysed for urgent attention 
due to poor metabolic control, the use of resources included are visits to emergency 
department, income, length of hospital stay and additional consultations. results: 
The evolution of the domains in satisfaction goes from 35.9 at baseline to 31.5 at 
6 months. The impact improves from 27.9 at baseline to 26.0 at 6 months, social/
vocational concern 25, 8 to 22.4 as well as concerns related to diabetes from 37.7 
to 33, 1. Also the degree of perceived improvement in VAS was 2.1 points. All ana-
lysed results were statistically significant. At baseline there were 26 patients (7.9%) 
who required urgent attention due to poor metabolic control in the previous 3 
months versus 9 patients (2.8) who requested urgent attention on data collected at 
6 months. ConClusions: CONTOUR USB device to measure glycemia and A1CNow 
device to measure HbA1C improve the quality of life of patients and reduce the use 
of resources due to poor control.
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objeCtives: Two surveys aimed to understand the impact of nocturnal and daytime 
non-severe hypoglycaemic events on health care system utilisation and patient 
quality of life. Methods: People with diabetes from six countries who had expe-
rienced a non-severe hypoglycaemic event in the 4 weeks prior to the survey were 
eligible (n= 300/survey). In South Africa, surveys were conducted online. results: 
In the South African nocturnal (N)/daytime (D) hypoglycaemia cohorts (n= 50/sur-
vey), 80% and 80% (N/D) had type 2 diabetes; 30%/24% (N/D) were male; mean age 
45/43 years (N/D); mean diabetes duration 11.1/9.4 years (N/D); 93/93% (N/D) insu-
lin users. 34/40% (N/D) experienced ≥ 1 non-severe hypoglycaemia events/week. 
Most respondents (70/76% [N/D]) were unemployed, which could skew the observed 
impact of hypoglycaemia on productivity. Both surveys revealed that, following 
an event, it took 20 min (median) for acute symptoms to disappear and 60 min 
(median) for the respondent to function at their normal level. After an event, 11/11% 
(N/D) decreased insulin dose, 14/12% (N/D) modified insulin administration time 
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objeCtives: CANA is a sodium glucose co-transporter 2 inhibitor developed for 
the treatment of T2DM. In a Phase 3 multi-national, randomised, double-blind, 
placebo- and active-controlled study, CANA improved glycaemia and reduced body 
weight and systolic blood pressure compared with placebo and SITA in subjects 
with T2DM on background metformin. Herein we report post-hoc analyses of the 
HRQoL and WRQoL data. Methods: WRQoL and HRQoL were measured using the 
Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and the 36-item Short Form 
(SF-36) at baseline, Week 26, and Week 52; with both instruments, higher scores 
indicate better quality of life. Data were analysed for CANA 100 (n= 368) and 300 
mg (n= 367), and SITA 100 mg (n= 366). Least-squares mean changes were evaluated 
using ANCOVA models; gender, anti-hyperglycaemic adjustment, baseline score, 
and treatment as covariates. results: Improvements from baseline to Weeks 26 
and 52 were detected for WRQoL total, physical function, and self-esteem scores in 
the CANA (both doses) and SITA groups (95% CI excludes zero), and for the other 
WRQoL domains, there was either improvement or no difference. A comparison 
of CANA 300 mg versus SITA at Week 26 suggests a difference in physical function 
(p= 0.0374). Improvements from baseline to Weeks 26 and 52 were also detected 
for HRQoL general health scores in the CANA (both doses) and SITA groups (95% 
CI excludes zero), and for other domains, there was either improvement or no 
difference. Other HRQoL results suggest possible differences in bodily pain (Week 
26, CANA 100 mg vs. SITA, p= 0.0518) and the mental component summary score 
(Week 52, CANA 300 mg vs. SITA, p= 0.0908). ConClusions: CANA and SITA were 
associated with improvements in WRQoL and HRQoL over 1 year in dual therapy. 
Results suggest that CANA is associated with a greater positive impact on patients 
versus SITA.
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objeCtives: With the increasing use of patient reported outcome measures in 
diabetes, it is important to understand which dimensions are most relevant to 
clinical indicators, and are the most predictive when assessing clinical change over 
time. This is important as the PROM scores can help inform the development of 
tailored therapeutics by highlighting the psychosocial functioning and quality of life 
impacts of different treatments. The aim of this study is to assess the relationship 
between the Diabetes Health Profile (DHP-18) and diabetes specific clinical vari-
ables to investigate how the measure can be used in the assessment of the impacts 
of different related complications and treatments. Methods: The relationship 
between the DHP-18 and a number of variables, including diabetes specific and co-
morbid health complications and length of time diagnosed were assessed. This was 
done cross-sectionally and longitudinally using a large dataset of Type 1 and Type 
2 people with diabetes (n= 1,802) collected in one United Kingdom health authority 
area. The analysis was carried out using Ordinary Least Squares and Logit regres-
sion. results: The Psychological distress domain is significantly associated with 
eye and foot related complications, and a number of co-morbid conditions including 
depression. The Barriers to activity domain is significantly associated with eye and 
foot related complications, duration of diabetes and a range of co-morbid conditions. 
The Disinhibited eating domain is related to duration of diabetes and co morbid 
conditions such as bone and lung disease. The number of associated problems was 
also a key predictive variable. ConClusions: The findings indicate that there is 
relationship between psychosocial functioning as measured by the DHP-18 and a 
range of clinical indicators. Tailored therapeutics can be used to change or reduce 
clinical concerns while also impacting on a patient’s psychosocial functioning and 
quality of life, and the DHP can be used to efficiently measure this.
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objeCtives: Little is known about the impact of body mass index (BMI) on health-
related quality of life (HRQoL) for diabetics in the Korean population. The aim of 
this study was to estimate the association between BMI and HRQoL of type 2 dia-
betic patients in Korea. Methods: This study is a cross-sectional analysis of adults 
who participated in 4th (2007-2009) and 5th (2010-2011) Korean National Health and 
Nutritional Examination Survey(total, 42,347 participants). HRQoL was measured 
by EuroQoL five-dimension (EQ-5D) and its association with BMI was investigated 
in Korean diabetic patients, especially those who did not have adequate control of 
blood glucose (HbA1c ≥ 6.5). Multivariate linear regression was performed at p-value 
of 0.05 with the use of SAS software, version 9.2. results: Out of 42,347 partici-
pants, 9.04% had diagnosed of diabetes. Among 2,726 diabetic patients in Korea, 
we assessed the association in 1,838 patients (median age 63) whose diabetes was 
not adequately controlled. We found that BMI was significantly negative associated 
with HRQoL(-0.0038, p-value < 0.001), after adjusting for age, sex, education, income, 
marital status, smoking status, alcohol, HbA1c, insulin treatment status, oral anti-
diabetic drug therapy, history of hypertension/high cholesterol/high triglyceride 
prevalence, stress level, and depression for more than two weeks. EQ-5D index 
decreased with rising BMI in Korean diabetic patients with HbA1c ≥ 6.5(-0.0038, 
